AM095

CAS No. 1345614-59-6

AM095( —— )

Catalog No. M11385 CAS No. 1345614-59-6

AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73μM for recombinant human or mouse LPA1 respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 In Stock
5MG 87 In Stock
10MG 123 In Stock
25MG 230 In Stock
50MG 402 In Stock
100MG 582 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    AM095
  • Note
    Research use only, not for human use.
  • Brief Description
    AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73μM for recombinant human or mouse LPA1 respectively.
  • Description
    AM095 is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73μM for recombinant human or mouse LPA1 respectively.
  • In Vitro
    AM095 is a potent LPA1 receptor antagonist because it inhibits GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA1 with IC50 values of 0.98 and 0.73 μM, respectively. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA1 (IC50=778 nM) and human A2058 melanoma cells (IC50=233 nM). The IC50 of AM095 in the human LPA1 GTPγS binding assay is comparable with that of our previously published compound AM966 (IC50=0.98±0.17 μM) and the Debio-0719 compound (IC50=0.60±0.04 μM). AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA1. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
  • In Vivo
    AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. After oral (10 mg/kg) dosing in rats, AM095 plasma concentrations peaked at 2 h with a Cmax of 41 μM, thereafter decreasing to 10 nM by 24 h. After intravenous (2 mg/kg) dosing, a Cmax of 12 μM is observed within 15 min, which also decreased to approximately 10 nM by 24 h, yielding a t1/2 of 1.79 h. In dogs, a single oral dose of 5 mg/kg yielded a peak plasma concentration of 21 μM within 15 min of dosing, which then decreased to 10 nM by 24 h. In contrast, an intravenous dose of 2 mg/kg resulted in a Cmax of 11 μM within 15 min and decreased to 15 nM by 8 h, yielding a t1/2 of 1.5 h.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    LPA Receptor
  • Recptor
    LPA1
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    1345614-59-6
  • Formula Weight
    478.47
  • Molecular Formula
    C27H23N2NaO5
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)CC(=O)[O-].[Na+]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Swaney JS,et al. Journal of Pharmacology and Experimental Therapeutics (2011), 336(3), 693-700.
molnova catalog
related products
  • BMS-986278

    BMS-986278 is an orally active and potent hemophosphatidic acid receptor 1 (LPA1) antagonist with Kb values of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively.

  • 1-Oleoyl lysophospha...

    1-Oleoyl lysophosphatidic acid sodium salt is an Endogenous agonist of LPA1 and LPA2.

  • Radioprotectin-1

    Radioprotectin-1 is a selective agonist of LPA2 with EC50 of 25 nM for murine LPA2 GPCR and exerts radioprotective and radiomitigative action.